[Renin and aldosterone secretion under converting enzyme inhibition]

Area of Science:

• Endocrinology
• Pharmacology
• Renal Physiology

Background:

• The renin-angiotensin system (RAS) plays a crucial role in regulating blood pressure and aldosterone secretion.
• Converting enzyme inhibitors (CEI) block the conversion of angiotensin I to angiotensin II, impacting the RAS.
• Understanding mechanisms of aldosterone secretion independent of the RAS is essential for therapeutic development.

Purpose of the Study:

• To investigate the regulatory mechanisms of aldosterone secretion independent of the renin-angiotensin system.
• To analyze the effects of a CEI (SQ 14,225) on plasma renin activity (PRA) and aldosterone concentration (PA) in dogs.
• To examine the influence of various pharmacological agents on PRA and PA during CEI infusion.

Main Methods:

• Mongrel dogs were administered SQ 14,225 intravenously under pentobarbital anesthesia.
• Plasma renin activity (PRA) and aldosterone concentration (PA) were measured.
• The effects of angiotensin II, saline, propranolol, norepinephrine, pindolol, indomethacin, furosemide, KCl, and prostaglandins were evaluated during CEI infusion.

Main Results:

• SQ 14,225 administration significantly increased PRA and decreased PA.
• The CEI-induced increase in PRA was blocked by angiotensin II, saline, propranolol, and norepinephrine, but not by pindolol or indomethacin.
• Furosemide and prostaglandins increased PRA, and KCl increased PA, suggesting stimulation via the RAS.

Conclusions:

• The increase in PRA during CEI administration is attributed to reduced negative feedback from angiotensin II.
• CEI-induced PRA elevation may involve beta-receptors and baroreceptors, in addition to direct feedback mechanisms.
• Furosemide and prostaglandins likely stimulate aldosterone secretion through the renin-angiotensin system, not directly on the adrenal cortex.